Navigation Links
Solace Therapeutics, Inc. Announces CE Mark Approval
Date:10/1/2009

FRAMINGHAM, Mass., Oct. 1 /PRNewswire/ -- Solace Therapeutics, Inc., a medical device company focused on the development of non-surgical bladder control therapies announced today that it has received European CE mark approval for the Solace Intravesical System, and ISO 13485:2003 certification for the company's Framingham facility. The company is introducing its first product, an office-based therapy for Female Stress Urinary Incontinence at the International Continence Society Meeting in San Francisco on Friday, October 2, 2009.

"This certification and CE mark approval represent a significant achievement and major milestone for Solace," said Kevin Connors, chief executive officer of Solace Therapeutics. "Successfully completing this process allows us to move forward with the clinical development of the Solace Intravesical System in Europe.

Solace is introducing its first product, a non-surgical therapy for women with Stress Urinary Incontinence, to ICS members at their annual meeting on Friday. "Solace is targeting those patients that are dissatisfied with current therapies and choose to manage their urinary leakage with absorbent pads or diapers," said Connors. "Solace has developed a new option for these patients."

The Solace Balloon is a small lightweight device (about the size of a quarter) that floats within the urinary bladder. It acts as a "shock absorber" to reduce the temporary pressure changes in the bladder that cause urinary leakage. It is placed in the bladder with a soft tube-like catheter and inflated with air. The 5 minute procedure is performed in the physician's office without anesthesia or surgery. No lifestyle change is required after the procedure, and the procedure is reversible at any time.

The Solace Balloon for women with involuntary urine leakage is currently being evaluated in several centers throughout the U.S. in an FDA IDE approved clinical trial. More information about the product is available at www.bladdercomfort.com.

About Solace Therapeutics

Solace Therapeutics is an emerging medical device company focused on the development of non-surgical office based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). Solace is dedicated to improving the patient's quality of life by eliminating side effects typically associated with current drug and surgical therapies. Solace's proprietary technology is designed to offer patients the following benefits:

  • Office-based therapy that does not require anesthesia or surgery
  • No lifestyle change required, before or after treatment
  • Reversible at any time

Solace's patented technology platform is based on the fundamental fluid mechanics principles of reducing rapid pressure changes in fluid with air-based pressure attenuation. Solace is the pioneer of applying these principles to treat bladder dysfunction. More information on Solace contact Kevin Connors at kconnors@solacetx.com or visit www.solacetx.com.

SOURCE Solace Therapeutics, Inc.


'/>"/>
SOURCE Solace Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... --Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the start ... hands-on learning experience is a 12-week summer program, May ... and Internship programs bring participants to ... are provided optional housing free of charge through Diplomat ... Riverfront Residence Hall to foster communication and collaboration among ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... managed services today announced a strategic partnership with Five9 (Nasdaq: FIVN), a ... Altura, one of Avaya’s largest Platinum Business Partners, is a leading provider ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... Center at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The ... surgical services into a single site. , The new 2 story building houses ...
(Date:5/24/2016)... ... May 24, 2016 , ... New Brunswick, New Jersey: This year marks Children’s ... fullest potential. To commemorate the anniversary, the hospital has themed the milestone “Hats Off” ... Children’s Specialized Hospital Foundation on Saturday, May 21, at Johnson Park in Piscataway, New ...
(Date:5/24/2016)... Bahama (PRWEB) , ... May 24, 2016 , ... Regenerative ... Such breakthroughs in adult stem cell therapy technology, protocols and patient results as have ... emerging field to become a more accessible standard of care for patients worldwide. , ...
(Date:5/24/2016)... ... , ... Loma Linda University Health (LLUH) has officially broken ground on the ... 3,000 people looked on as the shovels hit the dirt at the community groundbreaking ... During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of ...
Breaking Medicine News(10 mins):